Kodiak Sciences (KOD) Cash & Equivalents (2017 - 2026)

Kodiak Sciences (KOD) has 10 years of Cash & Equivalents data on file, last reported at $169.5 million in Q1 2026.

• Quarterly Cash & Equivalents rose 22.09% year-over-year to $169.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $169.5 million (up 22.09% YoY) and the FY2025 annual result came in at $209.9 million, up 24.86% from the prior year.
• Cash & Equivalents eased to $169.5 million in Q1 2026, from $209.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $671.7 million in Q1 2022 to a low of $72.0 million in Q3 2025.
• A 5-year average of $239.5 million and a median of $197.9 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 80.4% — and 2023, when it soared 119.27%.
• Tracing KOD's Cash & Equivalents over 5 years: stood at $196.8 million in 2022, then soared by 45.11% to $285.5 million in 2023, then sank by 41.13% to $168.1 million in 2024, then climbed by 24.86% to $209.9 million in 2025, then slipped by 19.22% to $169.5 million in 2026.
• The last three Cash & Equivalents figures came in at $169.5 million (Q1 2026), $209.9 million (Q4 2025), and $72.0 million (Q3 2025), per Business Quant data.